Abstract
e15556 Background: Everolimus (RAD001), as a new inhibitor for mammalian target of rapamycin (mTOR) provides clinical benefit to patients with anti-VEGF-refractory metastatic renal cell carcinoma (mRCC). However, factors for selection of patients who will benefit from Everolimus remain uncovered. Here we aimed to explore the potential molecular indicators for mRCC patients who may benefit from everolimus treatment. Methods: Paraffin-embedded tumor tissue specimens derived from 18 mRCC patients, who participated the phase 1b trial of everolimus in VEGF receptor (VEGFR)-tyrosine kinase inhibitor (TKI)-refractory Chinese patients with mRCC, were examined for the expression levels of phosphorylated AKT, mTOR, eukaryotic initiation factor 4E (eIF4E) binding protein-1 (4EBP1) and 40S ribosomal protein S6 (S6RP) by immunohistochemistry. Clinical benefit rate (complete response [CR], partial response [PR], plus stable disease [SD] ≥6 months) and progression-free survival time (PFS) were correlated with expression...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
